Annexon (ANNX) Other Working Capital Changes (2019 - 2026)
Annexon (ANNX) posted quarterly Other Working Capital Changes of -$605000.0 for Q1 2026, down 2850.0% year-over-year from $22000.0 in Q1 2025, and down 137.25% quarter-over-quarter from -$255000.0 in Q4 2025.
Analysis
Annexon (ANNX) Other Working Capital Changes (2019 - 2026) Analysis & Trends
Annexon's Other Working Capital Changes history runs 8 years deep, the most recent figure standing at -$605000.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 2850.0% year-over-year to -$605000.0; the TTM figure through Mar 2026 stood at -$1.2 million (up 6.27% YoY), while the FY2025 annual figure was -$598000.0, down 299.33% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at -$605000.0, down from -$255000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $1.6 million in Q1 2024, with the low at -$2.8 million in Q2 2024.
- The 5-year median for Other Working Capital Changes is -$255000.0 (2025), against an average of -$114294.1.
- The sharpest annual moves came in 2024 and 2026: Other Working Capital Changes surged 570.0% in 2024, then plunged 2850.0% in 2026.
- Annexon's Other Working Capital Changes stood at $259000.0 in 2022, then tumbled by 84.56% to $40000.0 in 2023, then soared by 570.0% to $268000.0 in 2024, then sank by 195.15% to -$255000.0 in 2025, then sank by 137.25% to -$605000.0 in 2026.
- Business Quant data shows ANNX's Other Working Capital Changes at -$605000.0 in Q1 2026, -$255000.0 in Q4 2025, and $999000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Annexon | 982.93 Mn | 982.93 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -783,000.00 |
| Jun 30, 2026 | -783,000.00 |
| Mar 31, 2026 | -767,000.00 |
| Mar 31, 2026 | -767,000.00 |
| Dec 31, 2025 | -737,000.00 |
| Dec 31, 2025 | -737,000.00 |
| Sep 30, 2025 | -692,000.00 |
| Sep 30, 2025 | -692,000.00 |
| Jun 30, 2025 | -678,000.00 |
| Jun 30, 2025 | -678,000.00 |
| Mar 31, 2025 | -664,000.00 |
| Mar 31, 2025 | -664,000.00 |
| Dec 31, 2024 | -635,000.00 |
| Dec 31, 2024 | -635,000.00 |
| Sep 30, 2024 | -596,000.00 |
| Sep 30, 2024 | -596,000.00 |
| Jun 30, 2024 | -2.78 Mn |
| Jun 30, 2024 | -2.78 Mn |
| Mar 31, 2024 | 1.63 Mn |
| Mar 31, 2024 | 1.63 Mn |